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Purpose: The treatment of a clinically node-positive (cN+) neck is important in 
the management of oral cavity squamous cell carcinoma (OSCC). However, the 
extent of neck dissection (ND) remains controversial. The purpose of our study 
was to evaluate whether level IV or V can be excluded in therapeutic ND for cN+ 
OSCC patients. Materials and Methods: We performed a retrospective chart re-
view of 92 patients who underwent a comprehensive or selective ND as a thera-
peutic treatment of cN+ OSCC from January 1993 to February 2009. Results: The 
incidence rate of metastasis to level IV or V was 22% (16 of 72) on the ipsilateral 
neck. Of 67 cases without clinically suspicious nodes at level IV or V, 11 cases 
(16%, 11 of 67) had pathologically proven lymphatic metastasis to level IV or V. 
Only a nodal staging above N2b was significantly relevant with the higher rate of 
level IV or V lymph node metastasis (p=0.025). In this series, selective ND, com-
bined with proper adjuvant therapy, achieved regional control and survival rates 
comparable to comprehensive ND in patients under the N stage of cN2a OSCC. 
Conclusion: In conclusion, level IV and V patients can avoid recurrence under 
cN2a OSCC.
Key Words:   Oral cavity cancer, selective neck dissection, therapeutic neck dis-
section, level IV, level V
INTRODUCTION
The primary goals of treatment of oral cavity squamous cell carcinoma (OSCC) are 
to control the local disease, eliminate the neck node metastasis, and prevent distant 
metastasis. Of these, the importance of regional control cannot be overemphasized 
because cervical lymph node metastasis is the single most potent prognostic factor 
of OSCC, and locoregional control is also known as a strong predictor of distant 
metastasis.1,2 About half of the patients with OSCC had pathologically positive 
lymph node metastases at the time of diagnosis, either clinically or subclinically.3,4 
Therefore, the treatment of a clinically node-positive (cN+) neck is very important 
in the management of OSCC.
However, the extent of neck dissection (ND) remains controversial. Since the 
time when the surgical treatment of the neck had started as the classical radical ND 
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gin of primary tumor, T stage, N stage based on the criteria 
of the American Joint Committee on Cancer (2009), and 
the type of surgery performed. All patients were preopera-
tively determined as clinically N+, with the clinical N+ 
neck defined as cervical lymph nodes detected at the physi-
cal examination, imaging studies (either a computed to-
mography scan, magnetic resonance imaging or positron 
emission tomography scan), or fine needle aspiration cytol-
ogy. The Institutional Review Board of Yonsei University 
College of Medicine approved this retrospective study.
This study included 57 males and 15 females in the CND 
group and 17 males and 3 females in the SND group. The 
mean age was 53 years (range: 20-79) in the CND group and 
56 years (range: 35-73) in the SND group. The distribution 
of primary sites is shown in Table 1. Table 2 and 3 summa-
rize the clinical stages of all the cases. The age, sex and clini-
cal stage were not different in both groups (data not shown).
During ND, the contents of the level IV and V specimen 
were dissected, labeled and processed separately from the 
main neck dissection specimen. Surgical specimens were 
then sent to the Pathology Department for permanent sec-
tion analysis. Histopathologic examination of the metasta-
ses included identifying the number and location of the 
nodes containing metastatic disease. The relationship be-
tween level IV or V lymph node metastasis and clinico-
pathologic predictive factors was assessed.
We compared the survival rates of cN1 or cN2a patients 
treated by CND or SND. Thirty-four patients were treated 
with CND and 20 patients with SND. The follow-up period 
ranged from 5 to 182 months (mean follow-up: 47 months). 
Patients were followed up for the minimum of two years, 
or until death. The actuarial 2-year disease-free survival 
rates were generated.
Statistical analysis was done with the Fisher’s exact test, 
Mann-Whitney U test, Kaplan-Meier method and log-rank 
test. Statistical significance was defined as p<0.05. 
 
RESULTS
 
Treatment of cervical lymph nodes
In the CND group, ipsilateral CNDs were performed in 72 
patients; radical, modified radical, or extended radical NDs 
in 15, 49, or 8 necks, respectively. The contra-lateral neck 
was managed with RND in 5, SND I-III in 42, and observa-
tion in 25 patients. An average of 39.3 (range 18-75) lymph 
nodes were collected from each neck. The mean number of 
(RND), there has been a lot of improvement in the aspect 
of reducing morbidity or extent of treatment. Comprehen-
sive ND (CND) including all levels of the neck has been 
accepted as the standard treatment for cN+ OSCC in many 
countries, but selective ND (SND) followed by adjuvant 
therapy such as radiotherapy or chemo-radiotherapy also 
has been performed in other institutes.5-7 In order to decide 
the extent of ND, we investigated the incidence of level IV 
or V lymph node metastases, attempted to identify the pre-
dictive factors of metastasis in cN+ OSCC patients, and 
compared the survival rate of cN+ OSCC patients treated 
with SND or CND. The purpose of our study was to deter-
mine whether level IV or V could be excluded in therapeu-
tic ND for cN+ OSCC patients.
MATERIALS AND METHODS
　　　
We retrospectively reviewed the charts of previously un-
treated OSCC patients who were treated at the Yonsei Head 
and Neck Cancer Clinic between January 1993 and Febru-
ary 2009. Only patients who met the following criteria 
were included: 1) the initial treatment was a simultaneous 
curative surgery on the primary tumor and the neck and 2) 
therapeutic ND (radical/modified radical ND or SND) was 
performed for the treatment of a clinically node-positive 
neck. We excluded patients 1) whose initial treatment was 
radiotherapy or chemotherapy, 2) had presence of other si-
multaneous primary tumors, or 3) had distant metastasis at 
the time of initial presentation. 
We proceeded with this study in two categories. First, we 
investigated the incidence of level IV or V lymph node me-
tastases and identified the predictive factors of level IV or V 
metastasis in cN+ OSCC patients who were treated with 
CND. Second, we compared the survival rate or regional 
recurrence of cN+ OSCC patients who were treated with 
SND including level I, II and III (SND I-III) or CND. Prior 
to 2005, authors performed CND for the treatment of cN+ 
OSCC patients, but since 2005, the policy changed so that 
for the cases with cN1 or cN2a, we performed SND I-III. 
Therefore, we compared the oncologic outcome of cN1 or 
cN2a OSCC patients who were treated before 2005 with 
patients after 2005. Consequently, a total of 92 patients 
were included in this study-72 in the CND group and 20 in 
the SND group. Seventy-two patients of the CND group 
also included 34 patients with cN1 or cN2a necks. 
Patients’ charts were reviewed regarding age, gender, ori-
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lymph nodes, but none were detected pre-operatively. The 
occult metastasis rate of level V was 7% (5 of 72), and the 
clinical N stage of these patients were cN2b in four cases 
and cN2c in one.
Six patients were clinically suspected to have bilateral 
metastasis (Table 2). One patient who had a suspicious node 
only in contra-lateral level I was treated with SND (I-III), 
while the remaining five cases underwent comprehensive 
ND. Contra-lateral level IV or V involvement was con-
firmed in three cases (Table 3). No patients had been detect-
ed to have contra-lateral level IV or V metastasis pre-opera-
tively, and all patients who had contra-lateral level IV or V 
metastasis were diagnosed with advanced T stage (all T4a) 
and had multiple neck nodes in the contra-lateral neck. 
However, we found no statistically significant predictive 
factor for contra-lateral level IV or V metastasis because of 
the small number of patients.
We analyzed the relationship between level IV or V lymph 
node metastasis and several clinicopathologic factors in 67 
patients with clinically positive nodes within neck level I, II 
lymph nodes harvested from each level was as follows: 4.1 
(range 0-15) from level I, 12.5 (range 2-24) from level II, 
7.7 (range 1-20) from level III, 7.2 (range 1-22) from level 
IV and 8.3 (range 1-19) from level V.
In the SND group, SND I-III was performed in 20 pa-
tients for the treatment of cN1 or cN2a neck. The contra-
lateral neck was managed with SND I-III in 12 and obser-
vation in 8 patients. 
Patients received postoperative radiotherapy if they had 
at least one of the following criteria: 1) multiple lymph 
node metastases, 2) extracapsular spread of the metastases 
on histopathological evaluation of the material from the 
neck dissection, 3) the resected primary tumor demonstrat-
ed a positive or very close margin, or 4) the primary tumor 
was stage 3 or 4. In the CND group, 28 out of 34 cN1, 
cN2a patients received postoperative radiotherapy. Postop-
erative radiotherapy was performed after initial surgical 
treatment in 17 out of 20 SND patients. The mean dose in 
the CND and SND group were 58.4 Gy (range, 50.4-66.8 
Gy) and 58.9 Gy (range, 50.4-74.4 Gy), respectively.
The incidence of level IV or V metastases and predictive 
factor
From the 72 patients that were evaluated, 62 (86%) were re-
vealed to have lymph node metastases by pathologic exami-
nation. Of these 62 patients, 60 had ipsilateral positive lymph 
nodes, while the remaining two had contra-lateral lymph 
nodes only. Fourty-five percent (27 of 60) of patients had ip-
silateral metastatic lymph nodes at a single level and 55% 
(33 of 60) at multiple levels. Level I and II were most fre-
quently affected on the ipsilateral side, with a similar preva-
lence of 45.8% (33 of 72). The distribution of pathologically 
positive lymph nodes by level is described in Table 3.
The incidence rate of metastasis to level IV or V was 22% 
(16 of 72) on the ipsilateral neck. 11 patients were revealed 
to have nodal metastasis in level IV, 1 in level V, and 4 in 
level IV and V. Of those 16 patients, 5 had clinically suspi-
cious metastatic nodes on level IV and the remaining 11 did 
not. Therefore, all five cases that were preoperatively sus-
pected to have metastatic nodes at level IV eventually were 
revealed to have pathologic positive nodes in level IV. There 
was no patient who was suspected to have level V metasta-
sis pre-operatively. Of the 67 cases that were believed to 
have a clinically node-negative level IV neck, 11 cases were 
histologically proven to have level IV metastases. Therefore, 
the occult metastasis rate of level IV was 16% (11 of 67). In 
level V, there were five cases with pathologically positive 
Table 1. Primary Site of Carcinoma
Site
Comprehensive 
ND group (%)
Selective 
ND group (%)
Alveolar ridge   5 (7)   2 (10)
Buccal mucosa   7 (10)   2 (10)
Floor of mouth 10 (14)   3 (15)
Hard palate   1 (1.3)   0
Lip   1 (1.3)   0
Retromolar trigone   3 (4)   2 (10)
Oral tongue 45 (62.5) 11 (55)
Total 72 (100) 20 (100)
ND, neck dissection.
Table 2. Clinical Staging for Comprehensive ND Group (n=72)
T1 T2 T3 T4 Total
N1 5 14 2   8 29
N2a 1   1 2   1   5
N2b 2   7 5 16 30
N2c 0   1 0   5   6
N3 0   2 0   0   2
Total 8 25 9 30 72
ND, neck dissection.
Table 3. Clinical Staging for Selective ND Group (n=20)
T1 T2 T3 T4 Total
N1 3 6 1 1 11
N2a 1 2 2 4   9
Total 4 8 3 5 20
ND, neck dissection.
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(p=0.025) (Table 5) and level V lymph node metastasis 
(p=0.036). 
Survival rate and regional recurrence
In the CND group, nine patients (26.4%) died of tumors, 
five (14.2%) died of causes unrelated to OSCC, and 20 pa-
tients (59%) were alive and free of cancer at the time of final 
follow-up. Of the nine patients who died of tumors, local 
failure developed in three patients, regional or locoregional 
failure in three, and distant failure in the remaining three. In 
the SND group, six patients (30%) died of tumors, two 
(10%) died of causes unrelated OSCC and 12 patients 
(60%) were alive and free of cancer. Local failure occurred 
in two patients, regional failure in three, and distant failure 
in one.
Regional recurrence (RR) occurred in four and three pa-
tients in the CND and SND group, respectively. In the 
CND group, RR developed in the ipsilateral dissected neck 
in three patients and one in contralateral undissected neck, 
while all recurrences occurred within the ipsilateral field of 
dissection in the SND group. There was no RR in level IV 
or V in either group. The CND patient who had recurred in 
the contralateral undissected neck was reoperated success-
fully with salvage ND followed by postoperative chemora-
diotherapy, but the remaining six patients died of recurred 
neck disease. The clinical information of these patients are 
described in Table 6.
Calculated by the Kaplan-Meier method, the 2-year actuari-
al disease-free survival rate was 71.8% in the CND group and 
69.2% in the SND group, and difference was not statistically 
significant (p=0.823). Similar to the disease-free survival, the 
2-year neck control rate of both groups were not statistically 
different (CND 88.0% vs. SND 84.0%, p=0.719) (Fig. 1). 
DISCUSSION
It is well known that the surgical removal of cancer is one of 
the most important treatment in OSCC and locoregional con-
trol is closely connected with survival.8,9 In addition, the most 
common cause of treatment failure of OSCC is known to be 
nodal failure. As it is extremely difficult to salvage from re-
currence after initial surgery,8 the first surgical management 
of the neck should include proper extent if indicated. 
Classical RND was accepted as the treatment of choice 
in neck management of head and neck cancers since 1906 
when it was first described by Crile. However, performing 
or III. There were no statistically significant differences in 
age, sex, clinical T stage, or histologic grade. Only a nodal 
staging above N2b was significantly relevant with level IV 
Table 4. Distribution of Pathologically Positive Lymph Node 
by Level
Level No. of Pts Cases with contra-lateral LN
No ipsilateral 
  LN
12 Only CI (1), only CIII, CIV (1)
I 11 I+CI (1)
II 12
II+CII (1), II+CI, CII (1), II+CII,  
  CIII (1)
III   5 III+CII (1)
IV   4
I, II   8 I, II+CI, CIII (1)
I, III   3 I, III+CI (1), I, III+CI, CIII (1)
I, IV   2
II, III   3
II, IV   2 II, IV+CIII (1)
II, V   1
I ,II, III   2 I, II, III+CI, CII, CIII, CIV (1)
I, II, IV   1
I, III, V   1
I, IV, V   1
I, II, III, IV   2
I, II, III, V   1
I, II, III, IV, V   1 I, II, III, IV, V+CI, CII, CIV, CV (1)
Total 72 12
No., number; Pt, patient; LN, lymph node; C, contra-lateral.
Table 5. Clinicopathologic Factors Affecting Level IV Lymph 
Node Metastasis 
Variables
Pts with positive level IV 
nodes, No. (%)
p value
Age (yrs) 0.262
    <50   5/22 (23)
    ≥50   6/45 (13)
Gender 0.271
    Male 10/53 (19)
    Female   1/14  (7)
T stage 0.435
    T1+T2   4/29 (14)
    T3+T4   7/38 (18)
N stage   0.025*
    ≤N2a   2/33 (6)
    ≥N2b   9/34 (26)
Histologic grade 0.247
    WD   9/38 (24)
    MD   2/21 (10)
    PD   0/8 (0)
No., number.; Pt, patient ; WD, well differentiated; MD, moderate differ-
entiated; PD, poorly differentiated. 
*p<0.05. 
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However, there are many widely known long-term morbid-
ities caused by chemo-radiotherapy, such as xerostomia, 
dysphagia or neck fibrosis.17,18 If we could accurately pre-
dict the possibility of nodal metastasis with the patients’ 
clinical characteristics and remove the suspicious area ap-
propriately, we could decrease the severity of adjuvant ther-
apy. However, this study is only a retrospective study, so 
there is still a long way to go until we are able to precisely 
predict nodal metastasis and subsequently reduce the dos-
age or extent of adjuvant therapy. Future multi-center stud-
ies might be helpful in overcoming these obstacles.
Many authors have suggested that patients with a greater 
than 20% risk of occult metastases, based on the anatomic 
location and the T stage of the primary tumor, should un-
dergo elective ND.19,20 In this study, the occult metastasis 
rate of level IV in patients who have suspicious nodes in 
level I, II or III was 16% (11 of 67). However, the occult 
metastasis rate for level IV in patients under the N stage of 
cN2a was 6% (2 of 33) and 26% (9 of 34) in patients over 
cN2b. The difference between two groups was statistically 
RNDs risks causing surgical morbidities. Regarding level 
IV or V, there could be spinal accessory nerve injury,10 
phrenic nerve paralysis11 or chylous leakage.12,13 Therefore, 
there has been a general effort to reduce morbidity and over-
treatment when performing neck dissections. In OSCC, it 
has been reported that lymph node metastases usually occur 
in level I, II or III in several post-surgical pathologic stud-
ies.14,15 SND I-III is widely accepted as an elective treat-
ment for clinically node-negative OSCC patients, while 
comprehensive ND removing every neck node from level I 
to level V is still regarded as the standard treatment for clin-
ically node-positive OSCC patients in many institutes.9,14  
Several authors have reported equivalent regional control 
and survival rates with protocols of SND followed by adju-
vant therapy, such as radiotherapy or chemo-radiotherapy, 
compared to RND.5,6,16 However, most patients who had 
pathologically proven metastatic lymph nodes received 
high dose post-operative adjuvant therapy; therefore, it is 
difficult to assess whether the control of neck disease was 
accomplished by proper surgery or by adjuvant therapy. 
Table 6. Clinical Information of Patients with Regional Recurrence
Case No. Primary site cTN ND Recur Salvage
1 Oral tongue cT2N1 MRND Ipsilateral dissected CCRT, failed
2 Oral tongue cT4N2a MRND Ipsilateral dissected Refuse, failed
3 Oral tongue cT3N1 MRND Contralateral undissected ND+CCRT, salvaged
4 Buccal mucosa cT3N1 MRND Ipsilateral dissected CCRT, failed
5 Oral tongue cT3N1 SND Ipsilateral dissected ND+CCRT, failed
6 Oral tongue cT3N2a SND Ipsilateral dissected CCRT, failed
7 Oral tongue cT2N1 SND Ipsilateral dissected CCRT, failed
No., number; ND, neck dissection; MRND, modified radical neck dissection; SND, selective neck dissection; CCRT, concurrent chemoradiotherapy.  
Fig. 1. Disease-free survival and neck control rates according to neck dissection. (A) Disease-free survival. (B) Neck control rate. CND, comprehensive neck 
dissection; SND, selective neck dissection.
0.0 0.0
0.2 0.2
0.4 0.4
0.6 0.6
0.8 0.8
1.0 1.0
0 050 50100 100150 150200 200
Survival Neck control
p=0.823
p=0.719
 CND
 SND
 CND
 SND
A B
Yoo Seob Shin, et al.
Yonsei Med J   http://www.eymj.org   Volume 54   Number 1   January 2013144
GL, et al. Elective and therapeutic selective neck dissection. Oral 
Oncol 2006;42:14-25.
7. Ambrosch P, Kron M, Pradier O, Steiner W. Efficacy of selective 
neck dissection: a review of 503 cases of elective and therapeutic 
treatment of the neck in squamous cell carcinoma of the upper 
aerodigestive tract. Otolaryngol Head Neck Surg 2001;124:180-7.
8. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Re-
gional lymph node involvement and its significance in the devel-
opment of distant metastases in head and neck carcinoma. Cancer 
1993;71:452-6.
9. Nikolarakos D, Bell RB. Management of the node-positive neck 
in oral cancer. Oral Maxillofac Surg Clin North Am 2008;20:499-
511.
10. Dijkstra PU, van Wilgen PC, Buijs RP, Brendeke W, de Goede CJ, 
Kerst A, et al. Incidence of shoulder pain after neck dissection: a 
clinical explorative study for risk factors. Head Neck 2001;23: 
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17. Nguyen NP, Moltz CC, Frank C, Vos P, Smith HJ, Karlsson U, et 
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and neck cancer. Ann Oncol 2004;15:383-8.
18. Larson DL. Management of complications of radiotherapy of the 
head and neck. Surg Clin North Am 1986;66:169-82.
19. Weiss MH, Harrison LB, Isaacs RS. Use of decision analysis in 
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laryngol Head Neck Surg 1994;120:699-702.
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neck in oral squamous cell carcinoma. Laryngoscope 1999;109(7 
Pt 1):1160-4.
21. Lim YC, Koo BS, Lee JS, Choi EC. Level V lymph node dissec-
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2006;116:1232-5.
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.
significant in this series (p=0.025). Hence, we should con-
sider a removal of level IV lymph nodes in patients with an 
N stage higher than N2b. However, the occult metastasis 
rate to level V was 7% (5 of 72) and 13% (5 of 38) even in 
patients over cN2b. This result was similar with our previ-
ous report21 and other studies.22,23 
Based on these studies and our own clinical data, the poli-
cy of neck treatment for OSCC changed in 2005 and since 
then, patients under the N stage of cN2a have been treated 
with SND I-III rather than modified radical ND or RND. 
Therefore, we were able to compare the oncologic outcome 
of cN1 or cN2a OSCC patients according to neck treatment, 
CND or SND I-III. In this series, SND combined with proper 
adjuvant therapy, achieved a survival rate comparable to 
CND in patients under the N stage of cN2a OSCC. In addi-
tion, regional recurrence did not occur in level IV or V in ei-
ther group.
In conclusion, due to the low occult metastasis rate, equiv-
alent survival rate and regional control, level IV and V did 
not have regional recurrance in patients under cN2a OSCC, 
but the exclusion of level IV or V in the therapeutic ND in 
patients with an N stage higher than cN2b needs further in-
vestigation. Thus, we suggest level IV and V patients can 
avoid recurrence under cN2a OSCC patients.
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